The International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) 2025 is a key event for advancing neurodegenerative disease research, bringing together experts to discuss the latest breakthroughs. Quanterix is proud to contribute to this dialogue with its groundbreaking Simoa® technology, featured in over 80 posters, presentations, and sessions. Below, we are highlighting the presentation and 4 posters submitted by Quanterix on the power of Simoa in detecting and analyzing critical biomarkers in Alzheimer’s, Parkinson’s, and related disorders.

Oral Presentation:

ID 3109:

Session Name

7350 – FLUID BIOMARKERS AND IMAGING IN AD, PD , LBD. PSP AND SMALL- VESSEL DISEASE (ID 577)

Date: Saturday, April 5, 2025
Time: 8:40-10:40am
Room: Hall F1

Fully Automated Ultra-Sensitive Simoa Assays for Alzheimer’s-Related Amyloid and Tau Pathology: p-Tau 205 and p-Tau 212

Tau phosphorylation is a hallmark of Alzheimer’s pathology. Our ultrasensitive Simoa assays allow for precise, non-invasive measurement of p-Tau205 and p-Tau212 in serum, plasma, and CSF, showing strong correlation with disease progression markers such as PET imaging, cognitive decline, and brain atrophy. With further clinical validation, these assays have the potential to revolutionize biomarker-driven diagnostics and therapeutic development.

Posters:

SHIFT 02-355:  A Fully Automated Ultra-Sensitive Four-Plex Simoa Assay for BD-Tau, NfL, GFAP, and UCH-L1

Understanding Alzheimer’s pathology in blood requires advanced, precise tools. Our newly developed four-plex Simoa assay, Neurology 4-Plex D, enables the simultaneous quantification of BD-Tau, NfL, GFAP*, and UCH-L1* in serum, plasma, and cerebrospinal fluid (CSF). This highly sensitive digital immunoassay demonstrated strong clinical performance in the BioHermes cohort, effectively distinguishing PET amyloid positivity. With its ability to measure multiple neurodegeneration markers non-invasively, this assay is poised to enhance diagnostics and disease monitoring.

*GFAP and UCH-L1 are offered pursuant to a license from Banyan Biomarkers, Inc.  Banyan GFAP® and Banyan UCH-L1® are registered trademarks of Banyan Biomarkers.

SHIFT 02-111:  Ultra-Sensitive Simoa Digital Immunoassay for Parkinson’s Disease Biomarkers: Total and Phosphorylated (Ser-129) Alpha-Synuclein

Alpha-synuclein aggregation is central to Parkinson’s disease pathology. Our Simoa assays offer ultra-sensitive detection of total and pS129 alpha-synuclein in plasma and CSF, significantly reducing the reliance on invasive CSF collection. With high precision and low limits of detection, these assays provide a minimally invasive approach to patient stratification, disease progression tracking, and therapeutic response monitoring, supporting the development of future Parkinson’s treatments.

SHIFT 02-356:  Fully Automated Ultra-Sensitive Simoa Assay for Highly Precise Quantification of sTREM-2 in Human Plasma and CSF

Neuroinflammation plays a crucial role in Alzheimer’s and other neurodegenerative diseases. sTREM-2, a biomarker of microglial activation, is increasingly recognized for its role in disease progression. Our new Simoa sTREM2 assay provides precise, highly sensitive measurement of sTREM-2 in plasma and CSF, offering researchers a robust tool for studying neuroinflammation, disease mechanisms, and potential therapeutic targets.

SHIFT 02-110: Novel Ultra-Sensitive Simoa Digital Immunoassay for Detection of PSD-95 in Human Plasma, Serum, and CSF

PSD-95 is an emerging biomarker of synaptic dysfunction, which is a key feature of Alzheimer’s and Parkinson’s diseases. Our Simoa PSD-95 assay enables precise detection of PSD-95 across plasma, serum, and CSF, offering a less invasive alternative for studying synaptic integrity and disease progression. This breakthrough supports early diagnosis and facilitates the evaluation of therapies targeting synaptic health.

Shift 02-623: Clinical Validation of LucentAD Complete, An Algorithmic Lab Developed Test (LDT) for Amyloid Detection in Plasma

LucentAD Complete is a clinically validated, CLIA laboratory-developed test (LDT) designed to accurately assess amyloid risk in patients with objective cognitive symptoms. Leveraging a multi-biomarker algorithm that includes p-Tau 217, the test was optimized using data from two diverse clinical cohorts (Bio-Hermes and the Amsterdam Dementia Cohort) to achieve ≥90% accuracy. Additional biomarkers—amyloid ratio, NfL, and GFAP—were analyzed using multivariate logistic regression to refine diagnostic thresholds and minimize inconclusive results. Validation across 1,082 samples, including a longitudinal ADNI cohort, confirmed consistent performance, with a threefold reduction in the intermediate zone and a 93.3% mean positive predictive value. LucentAD Complete delivers a reliable, blood-based tool for precise amyloid risk stratification across varied patient populations.

Driving the Future of Neurodegenerative Disease Research

Quanterix remains committed to advancing neurodegenerative disease research through cutting-edge biomarker detection. Our contributions at AD/PD 2025 reinforce the impact of Simoa technology in enabling early diagnosis, disease monitoring, and therapeutic advancements. As we continue to push the boundaries of biomarker science, we look forward to fostering collaborations that bring us closer to breakthroughs in Alzheimer’s, Parkinson’s, and beyond. For more details on these studies and our participation at AD/PD 2025, click here.